Aug. 8, 2023 - DelNova Inc., is developing a rescue drug, ReViVox®, to resolve side effects that may result from botulinum neurotoxin treatment....
June 8, 2023 – DelNova to be featured in the upcoming list of Top 10 Biotech Startups 2022 as Editor’s Choice, on Life...
April 1, 2023 DelNova patent allowed in Europe: EP 3454855 A1 20190320 (EN) “TREATING OF SIDE-EFFECTS RESULTING FROM CHEMODENERVATION”...
June 1, 2022 – Mary Gardner has dedicated her entire career to the areas of innovation and commercialization for the pharma, biotech, and...
May 3, 2022 – What are the complications associated with Botulinum Neurotoxin therapies? Neurotoxins are administered by medical professionals and sold in the...
DelNova to be featured in the upcoming list of Top 10 Biotech Startups 2022 as Editor’s Choice, on Life Sciences Review Magazine...
DelNova announces advances in the development of the First ever product to reverse complications arising from botulinum toxins, such as BOTOX®, Dysport®, XEOMIN®,...
Steve Yoelin, M.D. is a board-certified ophthalmologist based in Orange County, CA, with approximately 20 years of experience in minimally invasive medical aesthetics,...
DelNova’s patent portfolio covers key markets worldwide....
Watch the video presentation....
